In a report released on April 24, Roger Song from Jefferies maintained a Buy rating on Aclaris Therapeutics (ACRS – Research Report), with a price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roger Song has given his Buy rating due to a combination of factors surrounding Aclaris Therapeutics’ promising pipeline and strategic developments. The company’s lead asset, ‘045 (TSLP mAb), has shown impressive Phase 2a data in atopic dermatitis (AD), with potential for superior efficacy and a favorable dosing regimen compared to existing treatments. This asset’s potency and binding affinity suggest a longer dosing interval, which could enhance patient compliance and outcomes.
Additionally, Aclaris is advancing other promising candidates, such as ‘052 and ‘2138, which further strengthen its position in the immunology and inflammation space. The company’s robust cash position of $204 million supports ongoing and future clinical trials, including the anticipated Phase 2b trial for ‘045. Despite some caution due to the lack of a placebo control in earlier trials, the overall data and strategic plans provide a strong foundation for future growth, justifying the Buy rating.
ACRS’s price has also changed slightly for the past six months – from $1.290 to $1.270, which is a -1.55% drop .